On October 4, 2023 MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), reported that it has received a milestone payment under MediciNova’s assignment agreement with Genzyme Corporation, a subsidiary of Sanofi (Press release, MediciNova, OCT 4, 2023, View Source [SID1234635655]). The milestone payment of $1 million is the result of the successful achievement of a clinical development milestone for a gene therapy product based on AAV (adeno-associated virus) vector technology that is covered under the assignment agreement.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!